Summary
By a sensitive and quantitative fluorometric assay, brain and plasma time-dependent concentration profiles were generated for phosphoramide mustard (PM) and active alkylating metabolites derived from cyclophosphamide (CPA) administration to rats. Whereas PM rapidly disappeared from plasma, with a monophasic half-life of 15.1 min, equimolar administration of CPA generated active metabolites in plasma that disappeared monoexponentially, with a composite half-life of 63 min. As a consequence, the time-dependent concentration integral of active alkylating metabolites derived from CPA administration, calculated between 5 min and infinity, was 3-fold that of PM. Pharmacokinetic parameters were calculated for each compound. The brain/plasma concentration-integral ratios of PM and active alkylating metabolites derived from CPA were 0.18 and 0.20, respectively. The cerebrovascular permeability-surface area product of PM was 7.5×10−5s−1, which is similar to that of other watersoluble anticancer agents that are restricted from entering the brain. The activities of a range of daily doses of PM and CPA were assessed against subcutaneous and intracerebral implants of Walker 256 carcinosarcoma tumor in rats. Inhibition of subcutaneous tumor growth by 50% was caused by CPA and PM doses of 6.6 and 12.0 mg/kg (daily for 5 consecutive days, starting 36 h after tumor implantation), respectively. However, administration of daily doses of up to 40 mg/kg did not significantly increase the survival of animals with intracerebral tumor implants. These studies indicate that active metabolites of CPA are restricted from entering the brain and that only subtherapeutic concentrations are achieved in brain tissue after systemic administration of CPA or PM.
Similar content being viewed by others
Abbreviations
- CPA:
-
cyclophosphamide
- PM:
-
phosphoramide mustard
- 4-HC:
-
4-hydroxycyclophosphamide
- AP:
-
aldophosphamide
- PA:
-
cerebrovascular permeability-surface area product
References
Allen JC, Helson L (1981) High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749–756
Arndt CAS, Balis FM, McCully CL, Colvin OM, Poplack DG (1988) Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 48: 2113–2115
Bielicki L, Voelcker G, Hohorst HJ (1983) Enzymatic toxicogenation of “activated” cyclophosphamide by 3′–5′ exonuclease. J Cancer Res Clin Oncol 105: 27–29
Brock N, Hohorst HJ (1963) Über die Aktivierung von Cyclophosphamide in vivo und in vitro. Arzneimittelforschung 13: 1022–1031
Carter SK, Bakowski MT, Hellmann K (eds) (1987) Chemotherapy of cancer. 3rd ed. Wiley Medical, New York
Colvin M, Padgett CA, Fenselau C (1973) A biologically active metabolite of cyclophosphamide. Cancer Res 33: 915–918
Colvin M, Brundrett RB, Kan M-N, Jardine I, Fenselau C (1976) Alkylating properties of phosphoramide mustard. Cancer Res 36: 1121–1126
Connors TA, Grover PL, McLoughlin AM (1970) Microsomal activation of cyclophosphamide in vivo. Biochem Pharmacol 19: 1533–1535
Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115–129
Cornbleet MA, Leonard RCF, Smyth JF (1984) High-dose alkylating agent therapy: a review of clinical experiences. Cancer Drug Deliv 1: 227–238
Domeyer BE, Sladek NE (1980) Kinetics of cyclophosphamide biotransformation in vivo. Cancer Res 40: 174–180
Dorr R, Fritz W (eds) (1980) Cancer chemotherapy handbook. Kimpton, London
Draeger U, Peter G, Hohorst HJ (1976) Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 60: 355–359
Duncan JH, Colvin OM, Fenselau C (1973) Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicol Appl Pharmacol 24: 317–323
Egorin MJ, Kaplan RS, Salcman M, Aisner J, Colvin M, Wiernik PH, Bachur NR (1982) Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clin Pharmacol Ther 32: 122–128
Engle TW, Zon G, Egan W (1982) [31P]-NMR kinetic studies of the intra- and intermolecular alkylation chemistry of phosphoramide mustard and cognateN-phosphorylated derivatives ofN,N-bis(2-chloroethyl)amine. J Med Chem 25: 1347–1357
Epstein J, Rosenthal RW, Ess RJ (1955) Use ofr-(4-nitrobenzyl)-pyridine as analytical reagent for ethylenimines and alkylating agents. Anal Chem 27: 1435–1439
Finklestein JZ, Tittle K, Meshnik R, Weiner J (1975) Murine neuroblastoma: further evaluation of the C1300 model with single anti-tumor agents. Cancer Chemother Rep 59: 975–983
Foley GE, Friedman OM, Drolet BP (1961) Studies on the mechanism of action of cytoxan-evidence of activation in vivo and in vitro. Cancer Res 21: 57–63
Friedman OM (1967) Studies of some newer phosphoramide mustards. Cancer Chemother Rep 51: 347–357
Friedman OM, Boger E (1961) Chlorimetric estimation of nitrogen mustard in aqueous media. Anal Chem 33: 906–910
Gershwin ME, Goetel EJ, Steinberg AD (1974) Cyclophosphamide: use in practice. Ann Intern Med 80: 531–540
Graul EH, Shaumloffel E, Hundeshagen H, Wilmanns H, Simon G (1967) Metabolism of radioactive cyclophosphamide: animal tests and clinical studies. Cancer 20: 896–899
Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1–28
Greig NH (1989) Brain tumors and the blood-tumor barrier. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation. vol 2. clinical studies. Plenum Press, New York, pp 77–106
Greig NH (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 1. Basic science aspects. Plenum Press, New York, pp 311–367
Greig NH, Jones H, Cavanagh J (1983) Blood-brain barrier integrity and host responses in experimental metastatic brain tumors. Clin Exp Metastasis 1: 229–246
Greig NH, Sweeney DJ, Rapoport SI (1987) Melphalan concentration-dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 32: 179–185
Heiss WD, Turnheim M, Mamoli B (1978) Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine. Eur J Cancer 14: 1191–1202
Jardine I, Feneselau C, Kan M-N, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res 38: 408–415
Juma FD, Rogers HJ, Trounce JR, Bradbrook ID (1978) Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1: 229–231
Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209–217
Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10: 327–335
Lenssen U, Hohorst HJ (1979) Zur Frage der Permeabilität vonN,N-bis(2-chloräthyl)-Phosphorsäurediamid in Tumorzellen. J Cancer Res Clin Oncol 93: 161–164
Low JE, Boch RF, Sladek NE (1982) Conversion of 4-hydroperoxy-cyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts. Cancer Res 42: 830–837
Miller R (1966) Simultaneous statistical inferences. McGraw-Hill, New York, pp 76–81
Neuwelt E (1989) The blood-brain barrier: does its disruption have a role in the treatment of central nervous system neoplasms? In: Neuwelt E (ed) Implications of the blood-brain barrier and its manipulation. Plenum Press, New York, pp 107–193
Neuwelt EA, Barnett PA, Frenkel EP (1984) Chemotherapeutic agents' permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 14: 154–160
Neuwelt E, Howieson J, Frenkel E, Specht D, Weigel R (1986) Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19: 573–582
Neuwelt E, Dahlborg SA, Goldman D, Dana B, Ramsey FL (1989) Significant prolongation of survival of primary CNS lymphoma patients by combination chemotherapy given in association with osmotic blood-brain barrier disruption. Proc Am Assoc Cancer Res 30: 264
Ninane J, Baurain R, Kraker J de, Ferster A, Trouet A, Cornu G (1989) Alkylating activity in serum, urine and CSF following highdose ifosfamide in children. Cancer Chemother Pharmacol 24 [Suppl]: S2-S6
Nomura K, Watanabe T, Nakamura O, Ohira M, Shibui S, Takakura K, Miki Y (1984) Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas. Neurosurg Rev 7: 13–22
Norpoth K (1969) Untersuchungen zur oxydativen Umsetzung von Endoxan in vivo und in vitro. Habilitationsschrift, Fach Physiologische Chemie, Westfälischen Wilhelms-Universität, Münster
Ohno K, Pettigrew KD, Rapoport SI (1978) Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235: H299-H307
Ohno K, Fredericks WR, Rapoport SI (1979) Osmotic opening of the blood-brain barrier to methotrexate in the rat. Surg Neurol 12: 323–328
Paoletti P, Knerich R, Adinolfi D, Butti G, Pezzotta S (1985) Therapy for central nervous system malignant tumors. In: Gerosa MA, Rosenblum MA, Tridente G (eds) Brain tumors: biopathology and therapy. Pergamon Press, Oxford, pp 223–235 (Advances in the biosciences, vol 58)
Powers JF, Sladek NE (1983) Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. Cancer Res 43: 1101–1106
Rapoport S (1976) blood-brain barrier in physiology and medicine. Raven Press, New York
Robinson PJ, Rapoport SI (1986) Kinetics of protein binding determine rates of uptake of drugs by brain. Am J Physiol 251: R1212-R1220
Robinson PJ, Rapoport SI (1990) Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab 10: 153–161
Sano K, Sato O, Hayakawa I (1966) Adjuvant therapy of brain tumors. Clin Surg 21: 37–46
Shapiro WR (1974) The chemotherapy of intracerebral vs subcutaneous murine gliomas. Arch Neurol 30: 222–226
Shapiro WR, Ausman JI, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: evaluation of BCNU, cyclophosphamide, mithramycin, and methotrexate. Cancer Res 30: 2401–2413
Simon G, Graul EH, Hundeshagen H (1965) Tracer-studien mit radioaktiv markiertem Cyclophosphamid bei Hirntumoren. Acta Neurochir (Wien) 13: 441–456
Sladek NE (1971) Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res 31: 901–908
Sladek NE (1987) Oxazaphosphorines. In: Powis G, Prough RA (eds) Metabolism and action of anti-cancer drugs. Taylor & Fräncis, London, pp 48–90
Sladek NE, Powers JF, Grage GM (1984) Half-life of oxazaphosphorines in biological fluids. Drug Metab Dispos 12: 553–559
Stewart DJ, Russell N, Atack EA, Quarrington A, Stolback L (1984) Cyclophosphamide, doxorubicin, vincristine and dexamethasone in the treatment of bulky CNS lymphoma. J Neuroncol 2: 289
Struck RF, Kirk MC, Witt MH, Laster WR Jr (1975) Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 2: 46–52
Sulings WJ, Struck RF, Wooley CW, Shannon WM (1978) Comparative disposition of phosphoramide mustard and other cyclophosphamide metabolites in the mouse using the salmonella/mutagenesis assay. Cancer Treat Rep 62: 1321–1328
Talha MRZ, Rogers HJ, Trounce JR (1980) Distribution and pharmacokinetics of cyclophosphamide in the rat. Br J Cancer 41: 140–142
Wagner T (1989) Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children — a comment. Cancer Chemother Pharmacol 24 [Suppl]: S7
Yamada R, Kanai N, Hayawaka T, Higashi H, Mogami H, Jinnai D (1968) Experimental studies on chemotherapy of brain tumor. Med J Osaka Univ 18:373–395
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Genka, S., Deutsch, J., Stahle, P.L. et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol. 27, 1–7 (1990). https://doi.org/10.1007/BF00689268
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689268